177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 1, 2015, Pages 79-88

  Agarwal, Krishan Kant ^a   Singla, Suhas ^a   Arora, Geetanjali ^a   Bal, Chandrasekhar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

177Lu EDTMP; Breast and prostate carcinoma; High dose; Low dose; Pain palliation

Indexed keywords

ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONATE LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; LUTETIUM ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONIC ACID; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND;

ADULT; ANALGESIA; ANEMIA; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CARCINOMA; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LOW DRUG DOSE; PHASE 2 CLINICAL TRIAL; PROSTATE CARCINOMA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; AGED; BONE NEOPLASMS; BREAST TUMOR; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; RADIATION DOSE; SECONDARY;

ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN MANAGEMENT; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOPHARMACEUTICALS;

EID: 84912034658     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2862-z     Document Type: Article

References (28)

1. Galasko CS. Diagnosis of skeletal metastases and assessment of response to treatment. Clin Orthop Relat Res. 1995;312:64–75.
2. Barnes EA. Radiopharmaceuticals for painful bone metastases: perspective from radiation oncology. J Support Oncol. 2011;9:208–9.
3. Fischer M, Kampen WU. Radionuclide therapy of bone metastases. Breast Care (Basel). 2012;7:100–7.
4. Shah Syed GM, Maken RN, Muzzaffar N, Shah MA, Rana F. Effective and economical option for pain palliation in prostate cancer with skeletal metastases: 32P therapy revisited. Nucl Med Commun. 1999;20:697–702.
5. Fang N, Li Y, Xu YS, Ma D, Fu P, Gao HQ, et al. Serum concentrations of IL-2 and TNF-alpha in patients with painful bone metastases: correlation with responses to 89SrCl2 therapy. J Nucl Med. 2006;47:242–6.
6. Maini CL, Bergomi S, Romano L, Sciuto R. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging. 2004;31 Suppl 1:S171–8.
7. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805–13.
8. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336–41.
9. Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, et al. Effects of low-dose cisplatin on strontium-89 therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43:79–86.
10. Chakraborty S, Das T, Banerjee S, Balogh L, Chaudhari PR, Sarma HD, et al. 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm. 2008;23:202–13.
11. Máthé D, Balogh L, Polyák A, Király R, Márián T, Pawlak D, et al. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent. Nucl Med Biol. 2010;37:215–26.
12. Chakraborty S, Das T, Unni PR, Sarma HD, Samuel G, Banerjee S, et al. 177Lu-labeled polyaminophosphonates as potential agents for bone pain palliation. Nucl Med Commun. 2002;23:67–74.
13. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239–53.
14. McCaffery M, Pasero C. Pain: clinical manual. St. Louis: Mosby; 1999. p. 16.
15. Crooks V, Waller S, Smith T, Hahn TJ. The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients. J Gerontol. 1991;46:M139–44.
16. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systemic review. Lancet Oncol. 2005;6:392–400.
17. Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet. 2000;355:1428–9.
18. Parker CC, Pascoe S, Chodacki A, O’Sullivan JM, Germá JR, O’Bryan-Tear CG, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63:189–97.
19. Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer. 2013;11:20–6.
20. Abbasi IA. Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation. Nucl Med Biol. 2011;38:417–25.
21. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, et al. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol. 2003;21:2869–75.
22. Kolesnikov-Gauthier H, Carpentier P, Depreux P, Vennin P, Caty A, Sulman C, et al. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med. 2000;41:1689–94.
23. Pons F, Herranz R, Garcia A, Vidal-Sicart S, Conill C, Grau JJ, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med. 1997;24:1210–4.
24. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993;34:1839–44.
25. Ahonen A, Joensuu H, Hiltunen J, Hannelin M, Heikkila J, Jakobsson M, et al. Samarium-153-EDTMP in bone metastases. J Nucl Biol Med. 1994;38:123–7.
26. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918–25.
27. Yuan J, Liu C, Liu X, Wang Y, Kuai D, Zhang G, et al. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer a phase II study. Clin Nucl Med. 2013;38:88–92.
28. Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun. 2007;28:623–30.